Your trusted source for investing success

Tag: treatment

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona’s gene therapy program ABO-202 for the treatment of

Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa

Krystal Biotech (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announces that KB103, a gene therapy candidate for dystrophic epidermolysis bullosa (“DEB”), was granted Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA).  KB103 represents the first

Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week PhaseOut DMD clinical trial. Top-line data from the full trial continue to be expected in the third quarter of 2018.

As quoted in the press release:

“We believe the early improvements seen

Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003

Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
5 Top Weekly NASDAQ Biotech Stocks: vTv Increases 163 Percent